Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies - PubMed (original) (raw)
Clinical Trial
. 2004 May;33(9):891-900.
doi: 10.1038/sj.bmt.1704477.
M Kami, S-W Kim, Y Onishi, Y Kishi, N Murashige, A Hori, R Kojima, M Sakiyama, O Imataki, Y Heike, R Tanosaki, S Masuo, S Miyakoshi, S Taniguchi, K Tobinai, Y Takaue
Affiliations
- PMID: 15048142
- DOI: 10.1038/sj.bmt.1704477
Clinical Trial
Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies
T Hamaki et al. Bone Marrow Transplant. 2004 May.
Abstract
The purpose of this study was to evaluate the feasibility and efficacy of allogeneic hematopoietic stem cell transplantation with a reduced-intensity regimen (RIST) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). In all, 36 patients (median age 55 years) underwent RIST from an HLA-matched related donor between September 1999 and December 2002. The diagnoses included AML (n=14), leukemia evolving from MDS (n=10), and MDS (refractory anemia with excess blasts n=6, refractory anemia n=6). The RIST regimen consisted of purine analog (cladribine or fludarabine)/busulfan, with or without antithymocyte globulin. The regimen was well tolerated, and 34 patients achieved durable engraftment and most achieved remission after RIST. A total of 17 patients developed grade II-IV acute GVHD, and 27 developed chronic GVHD. Eight patients relapsed, and five of them received antithymocyte globulin (ATG) as part of the preparative regimen. A total of 12 patients died (four disease progression, six transplantation-related complications, and two others). Estimated 1-year disease-free survival (DFS) in low- and high-risk groups was 85 and 64%, respectively. We conclude that RIST can be performed safely in elderly patients with myeloid malignancies, and has therapeutic potential for those who fail conventional chemotherapy. In view of the significant association between GVHD or ATG and DFS, defined management of GVHD following RIST should become a major target of clinical research.
Similar articles
- Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Saito T, Kanda Y, Kami M, Kato K, Shoji N, Kanai S, Ohnishi T, Kawano Y, Nakai K, Ogasawara T, Matsubara H, Makimoto A, Tanosaki R, Tobinai K, Wakasugi H, Takaue Y, Mineishi S. Saito T, et al. Clin Cancer Res. 2002 Apr;8(4):1014-20. Clin Cancer Res. 2002. PMID: 11948108 Clinical Trial. - Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR; German Cooperative Transplant Study Group. Kröger N, et al. Ann Hematol. 2003 Jun;82(6):336-42. doi: 10.1007/s00277-003-0654-9. Epub 2003 May 1. Ann Hematol. 2003. PMID: 12728337 Clinical Trial. - A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR. Kröger N, et al. Bone Marrow Transplant. 2001 Oct;28(7):643-7. doi: 10.1038/sj.bmt.1703215. Bone Marrow Transplant. 2001. PMID: 11704786 - Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'.
Kassim AA, Chinratanalab W, Ferrara JL, Mineishi S. Kassim AA, et al. Bone Marrow Transplant. 2005 Oct;36(7):565-74. doi: 10.1038/sj.bmt.1705075. Bone Marrow Transplant. 2005. PMID: 15995714 Review.
Cited by
- Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis.
Zhang ZH, Lian XY, Yao DM, He PF, Ma JC, Xu ZJ, Guo H, Zhang W, Lin J, Qian J. Zhang ZH, et al. J Cancer Res Clin Oncol. 2017 Sep;143(9):1853-1864. doi: 10.1007/s00432-017-2429-z. Epub 2017 May 3. J Cancer Res Clin Oncol. 2017. PMID: 28470473 Review. - Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
Valdez BC, Li Y, Murray D, Ji J, Liu Y, Popat U, Champlin RE, Andersson BS. Valdez BC, et al. Exp Hematol. 2015 Jun;43(6):448-61.e2. doi: 10.1016/j.exphem.2015.02.001. Epub 2015 Feb 19. Exp Hematol. 2015. PMID: 25704054 Free PMC article. - Cost and effectiveness of reduced-intensity and conventional allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome.
Imataki O, Kamioka T, Fukuda T, Tanosaki R, Takaue Y. Imataki O, et al. Support Care Cancer. 2010 Dec;18(12):1565-9. doi: 10.1007/s00520-009-0779-z. Epub 2009 Nov 22. Support Care Cancer. 2010. PMID: 20967555 - Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.
Valdez BC, Andersson BS. Valdez BC, et al. Environ Mol Mutagen. 2010 Jul;51(6):659-68. doi: 10.1002/em.20603. Environ Mol Mutagen. 2010. PMID: 20577993 Free PMC article. Review. - Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation.
Kondo T, Yasumoto A, Arita K, Sugita J, Shigematsu A, Okada K, Takahata M, Onozawa M, Kahata K, Takeda Y, Obara M, Yamamoto S, Endo T, Nishio M, Sato N, Tanaka J, Hashino S, Koike T, Asaka M, Imamura M. Kondo T, et al. Int J Hematol. 2010 Mar;91(2):310-21. doi: 10.1007/s12185-009-0487-y. Epub 2010 Jan 20. Int J Hematol. 2010. PMID: 20087795
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous